EBR Systems Inc (ASX: EBR) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


EBR Systems Inc Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $320.41 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 308.11 million
Earnings per share -0.120
Dividend per share N/A
Year To Date Return 65.57%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • EBR Systems Inc (ASX: EBR)
    Latest News

    Kid putting a coin in a piggy bank.
    Small Cap Shares

    'Plenty of upside': 2 ASX small-cap shares to buy while they're cheap

    One of these stocks has doubled since the start of the year. See what one expert is recommending to add…

    Read more »

    Three guys in shirts and ties give the thumbs down.
    Share Fallers

    Why Collins Foods, EBR, Gold Road, and Woodside shares are dropping today

    These ASX shares are ending the week deep in the red.

    Read more »

    a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
    Share Gainers

    Why Bigtincan, EBR, Gentrack, and New Hope shares are storming higher

    These ASX shares are having a strong start to the week.

    Read more »

    a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
    Healthcare Shares

    Do ASX biotech shares offer 'good buying' after the sell-off? Experts weigh in

    After some strong support in early 2021, biotechnology stocks took a beating over the past 6 months.

    Read more »

    EBR ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About EBR Systems Inc

    EBR Systems Inc is engaged in treatment for patients suffering from cardiac rhythm diseases by developing therapies using wireless cardiac stimulation. The company's Wise CRT System uses proprietary wireless technology to deliver pacing stimulation directly inside the left ventricle of the heart.

    EBR Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    14 Jun 2024 $1.04 $0.03 2.97% 192,487 $1.00 $1.04 $1.00
    13 Jun 2024 $1.01 $-0.03 -2.88% 127,419 $1.05 $1.05 $1.01
    12 Jun 2024 $1.04 $-0.08 -7.14% 402,934 $1.12 $1.12 $1.01
    11 Jun 2024 $1.12 $-0.03 -2.61% 116,677 $1.14 $1.14 $1.11
    07 Jun 2024 $1.15 $0.02 1.78% 112,862 $1.15 $1.15 $1.12
    06 Jun 2024 $1.13 $0.01 0.90% 89,950 $1.13 $1.15 $1.10
    05 Jun 2024 $1.11 $-0.09 -7.50% 249,369 $1.20 $1.20 $1.09
    04 Jun 2024 $1.20 $0.03 2.58% 201,524 $1.17 $1.20 $1.15
    03 Jun 2024 $1.17 $0.07 6.36% 337,571 $1.10 $1.18 $1.10
    31 May 2024 $1.10 $0.02 1.85% 226,557 $1.06 $1.13 $1.06
    30 May 2024 $1.08 $0.03 2.84% 83,522 $1.06 $1.09 $1.04
    29 May 2024 $1.06 $0.02 1.93% 117,538 $1.05 $1.08 $1.03
    28 May 2024 $1.04 $-0.05 -4.63% 138,835 $1.08 $1.08 $1.01
    27 May 2024 $1.08 $0.06 5.85% 120,409 $1.03 $1.10 $1.03
    24 May 2024 $1.03 $-0.05 -4.67% 55,476 $1.05 $1.06 $1.03
    23 May 2024 $1.07 $0.01 0.94% 41,292 $1.07 $1.07 $1.04
    22 May 2024 $1.06 $-0.08 -7.02% 232,312 $1.13 $1.13 $1.06
    21 May 2024 $1.14 $0.04 3.64% 220,703 $1.06 $1.15 $1.06
    20 May 2024 $1.10 $0.06 5.77% 266,558 $1.04 $1.10 $1.04
    17 May 2024 $1.04 $0.05 5.03% 116,872 $1.01 $1.04 $1.00
    16 May 2024 $1.00 $-0.01 -1.00% 126,318 $1.00 $1.00 $0.98

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    31 May 2024 Christopher Nave Issued 163,637 $180,000
    Issue of options.
    31 May 2024 Karen Drexler Issued 163,637 $180,000
    Issue of options.
    31 May 2024 Allan Will Issued 163,637 $180,000
    Issue of options.
    31 May 2024 Bronwyn Evans Issued 163,637 $180,000
    Issue of options.
    31 May 2024 David Steinhaus Issued 163,637 $180,000
    Issue of options.
    31 May 2024 John McCutcheon Issued 1,590,000 $1,749,000
    Issue of options.
    31 May 2024 Trevor Moody Issued 163,637 $180,000
    Issue of options.
    15 Mar 2024 Bronwyn Evans Buy 17,413 $13,059
    On-market trade. CDIs
    06 Mar 2024 Bronwyn Evans Buy 22,033 $17,866
    On-market trade.
    27 Nov 2023 Bronwyn Evans Buy 5,000 $3,042
    On-market trade. CDIs
    22 Nov 2023 Bronwyn Evans Buy 20,000 $12,961
    On-market trade. CDIs
    11 Aug 2023 John McCutcheon Issued 675,000 $597,375
    Issue of options.
    11 Aug 2023 David Steinhaus Issued 182,159 $161,210
    Issue of options.
    11 Aug 2023 Christopher Nave Issued 182,159 $161,210
    Issue of options.
    11 Aug 2023 Bronwyn Evans Issued 182,159 $161,210
    Issue of options.
    11 Aug 2023 Allan Will Issued 182,159 $161,210
    Issue of options.
    11 Aug 2023 Karen Drexler Issued 182,159 $161,210
    Issue of options.
    11 Aug 2023 Trevor Moody Issued 182,159 $161,210
    Issue of options.
    25 Jul 2023 Bronwyn Evans Buy 32,967 $30,000
    Participation in share purchase plan. CDIs

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Christopher Dean Nave Non-Executive Director Oct 2017
    Dr Nave is a Founder and Managing Director of Brandon Capital Partners and the CEO of the Medical Research Commercialization Fund. Dr Nave previously served as the Director of Commercialization at the Baker Heart Research Institute. Currently a Director of The Australian Investment Council, Azura Ophthalmics, Inc., Certa Therapeutics Pty Ltd., Global Kinetics Corporation Ltd., OccuRx Pty Ltd., Osprey Medical Inc., PolyActiva Pty Ltd., and Que Oncology, Inc. Dr Nave was Chairperson of Fibrotech Therapeutics Pty Ltd. at the time of its sale to Shire Plc and a Director of Spinifex Pharmaceuticals, Inc. at the time of its sale to Novartis International AG.
    Ms Karen Ruth Drexler Non-Executive Director Oct 2021
    Ms Drexler is entrepreneur with expertise in the fields of digital health, medical devices, and diagnostics. Currently serving on the boards of two other public companies, ResMed, Inc. and Outset Medical Inc., focusing on the compensation, nominating, and governance committees. Ms Drexler also serves on the boards of two private companies: VIDA Diagnostics Inc., an artificial intelligence-powered lung imaging solutions company, and Tivic Health Systems, Inc., a bioelectric medicine company focused on relief of congestion and sinus pain. She also acts as a senior strategic advisor for other early-stage companies and spent 11 years on the board of the Keller Center for Innovation in Engineering Education at Princeton University. Ms Drexler is an active mentor and advisor to Astia, a global nonprofit that supports high-potential female founders, as well as a mentor with StartX, the Stanford University incubator.
    Mr Allan Roger Will Executive ChairmanExecutive Director May 2003
    Mr Will is an operating executive with experience founding, funding, operating, and selling medical device companies. Prior to EBR Systems, he led the negotiation of Ardian's acquisition by Medtronic for over $800 million. Mr Will was also founding Managing Director at Split Rock Partners and a Partner at St. Paul Venture Capital. Previously, he was Founder, Chairman & CEO of The Foundry, co-founding 11 companies there including Ardian, Evalve (acquired by Abbott Laboratories for $450 million), and Concentric Medical (acquired by Stryker for $135 million). Earlier in his career, Mr Will served as CEO of AneuRx, acquired by Medtronic, growing to over $150 million the year of launch. Prior to that, he was President & CEO of Devices for Vascular Intervention, growing the business to 550 employees, $100 million revenue run rate, and acquisition by Eli Lilly. Mr Will holds more than 30 issued patents.
    Dr Bronwyn Joy Evans Non-Executive Director Oct 2021
    Dr Evans is a leader and CEO with a technical background across industry sectors, including medical technology, manufacturing, power generation and distribution, and technical regulation and standards. Currently the CEO of Engineers Australia, she also serves as the Chair of Building 4.0 CRC and as Director at GME Pty Ltd. Prior to her role with Engineers Australia, Dr Evans was the CEO of Standards Australia. She has previously held positions in innovation initiatives, including Chair of MTPConnect (the Industry Growth Center for Medical Technologies and Pharmaceuticals) and was a member of the Industry 4.0 Advanced Manufacturing Forum Leadership group. Dr Evans has been recognized as one of Australia's 100 most influential engineers and as one of 100 Women of Influence. She is an Honorary Fellow of the University of Wollongong and Engineers Australia and a Fellow of the Australian Academy of Technological Sciences and Engineering.
    Dr David Mark Steinhaus Non-Executive Director Oct 2021
    Dr Steinhaus retired in 2019 as Vice President and General Manager of the Heart Failure Business for the Cardiac Rhythm and Heart Failure Division at Medtronic plc. He joined Medtronic in 2005, after 20 years of cardiology (electrophysiology) practice. Dr Steinhaus' responsibilities at Medtronic included bringing the physician voice to CRHF, identifying future opportunities in new product development, and serving as a liaison to government agencies, professional societies, and medical groups. Closely associated with research and academia, performing clinical studies in implantable cardiac devices and leads, he served as Chair of the Department of Cardiology and Director of the Electrophysiology Department at the Mid America Heart Institute and St. Luke's Hospital and Director of the Electrophysiology Fellowship Program at the University of Missouri at Kansas City School of Medicine. Since leaving Medtronic, he has served as a consultant and board member to multiple medical device companies.
    Mr John Graham McCutcheon Chief Executive OfficerPresidentExecutive Director Jun 2019
    Mr McCutcheon has over 35 years of sales, marketing, and general management experience in medical devices. Mr McCutcheon started his career at American Hospital Supply (acquired by Baxter International) and has spent the past 20 years at start-ups, including DVI (acquired by Eli Lily), Perclose (acquired by Abbott Laboratories), Emphasys Medical (acquired by Pulmonx), Ventus Medical, and Ceterix Orthopaedics (acquired by Smith & Nephew). He has served on Boards including Emphasys Medical, Ventus Medical, Disc Dynamics, Zeltiq (ZLTQ), Advanced Stent Technologies (acquired by Boston Scientific), and LuMend (acquired by Johnson & Johnson).
    Mr Trevor John Moody Non-Executive Director Oct 2017
    Mr Moody served as Medical Device Partner at M.H. Carnegie & Co. (from October 2013 to April 2022), where he made investments in medical device companies. He has also served since January 2010 as President of TM Strategic Advisors LLC, a management consultancy. Mr Moody was previously a General Partner at Frazier Healthcare Ventures, a U.S. based private equity and venture capital firm. Currently a Director of Cardiac Dimensions Pty Ltd., Renew Medical Pty Ltd., The Brain Protection Company Pty Ltd., and CurvaFix, Inc., Mr Moody also serves on the board of Angel Flight West, a not-for-profit that provides free air transport for patients requiring long-distance travel for medical treatment.
    Mr Brendan Case Company Secretary
    Gary William Doherty Chief Financial Officer
    Spencer H. Kubo Chief Medical Officer
    Michael Hendricksen Chief Operating Officer
    Madhuri Bhat Chief Regulatory Officer
    N. Parker Willis Chief Technology Officer
    Brendan Case Company Secretary
    Andrew Shute Senior Vice President of Business Development
    John Hatchett Sellers Unites States Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Split Rock Partners LP 19,732,458 6.40%
    MRCF3 Services (H) Pty Ltd <MRCF3 (H) A/C> i 18,480,532 6.00%
    MRCF3 Services (HP) Pty Ltd <MRCF3 (HP) A/C> i 16,823,969 5.46%
    Carnegie Innovation Fund No 2 LP 14,162,839 4.60%
    CHV III LP 12,818,782 4.16%
    J P Morgan Nominees Australia Pty Limited 12,626,615 4.10%
    Argo Investments Limited 10,782,633 3.50%
    MRCF3 Services (HP) Pty Ltd <MRCF3 (HP) A/C> ii 10,203,745 3.31%
    MRCF3 Services Pty Ltd <MRCF3 (AS) A/C> 8,782,983 2.85%
    Carnegie Healthcare Fund LP 8,776,909 2.85%
    Hsbc Custody Nominees (Australia) Limited 8,479,971 2.75%
    SPVC VI LLC 6,996,473 2.27%
    MHC Fund Services B Pty Ltd <MHC HOSTPLUS Co-Invt A/C> 6,615,306 2.15%
    Carnegie Venture Captial Pty Ltd <Carnegie Healthcare F/LP A/C> 6,175,754 2.00%
    MRCF3 Services (SW) Pty Ltd <MRCF3 (SW) A/C> i 6,161,947 2.00%
    MRCF5 Services (TS) Pty Ltd <MRCF5 (TS) A/C> 6,111,111 1.98%
    Mr Allan Will <AR Will U/A DT 6/14/12 A/C> 5,827,224 1.89%
    MRCF3 Services (H) Pty Ltd <MRCF3 (H) A/C> ii 4,638,382 1.51%
    MRCF3 Services (SW) Pty Ltd <MRCF3 (SW) A/C> ii 4,629,630 1.50%
    UBS Nominees Pty Ltd 4,158,387 1.35%